Wiser et al., 2010
Night sweats affect a small percentage of users, primarily during the first four to eight weeks
In a recent Managed Healthcare Executive pharmacy survey, plan sponsors, providers and others were asked, How should payers respond to the rising cost of prescriptions for the GLP-1 drugs for weight loss? Most replied that such drugs should be covered only after other options have been tried first
Australian compounding pharmacies cannot legally compound retatrutide because it is not TGA approved
Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T (2017) Exenatide once weekly versus placebo in Parkinsons disease: a randomised, double-blind, placebo-controlled trial
The SoloStar pen became a competitive tool: Sanofi emphasized the pens ease of use and training resources, positioning device familiarity as a reason for patients and prescribers to stay on the branded product even as biosimilar insulins entered at substantially lower price points